Janux Therapeutics, Inc. (NASDAQ:JANX) Given Consensus Rating of “Moderate Buy” by Brokerages

Shares of Janux Therapeutics, Inc. (NASDAQ:JANX) have earned an average rating of “Moderate Buy” from the eight research firms that are currently covering the company, Marketbeat Ratings reports. One research analyst has rated the stock with a hold recommendation and seven have assigned a buy recommendation to the company. The average 1 year price objective among brokers that have updated their coverage on the stock in the last year is $66.29.

JANX has been the topic of several research reports. Jonestrading initiated coverage on Janux Therapeutics in a research report on Tuesday, April 16th. They set a “buy” rating and a $70.00 price objective on the stock. Scotiabank assumed coverage on Janux Therapeutics in a research note on Thursday, May 30th. They issued a “sector perform” rating and a $47.00 target price for the company. Cantor Fitzgerald reaffirmed an “overweight” rating and issued a $100.00 price target on shares of Janux Therapeutics in a research note on Thursday, May 9th. Wedbush increased their price objective on Janux Therapeutics from $53.00 to $74.00 and gave the stock an “outperform” rating in a report on Wednesday, May 8th. Finally, Bank of America boosted their target price on shares of Janux Therapeutics from $24.00 to $48.00 and gave the company a “buy” rating in a report on Wednesday, March 13th.

Janux Therapeutics Stock Up 3.8 %

NASDAQ:JANX opened at $41.89 on Friday. The firm’s fifty day simple moving average is $47.79 and its 200 day simple moving average is $31.85. The stock has a market cap of $2.17 billion, a P/E ratio of -34.34 and a beta of 3.71. Janux Therapeutics has a twelve month low of $5.65 and a twelve month high of $65.60.

Janux Therapeutics (NASDAQ:JANX) last posted its earnings results on Tuesday, May 7th. The company reported ($0.30) EPS for the quarter, topping the consensus estimate of ($0.35) by $0.05. Janux Therapeutics had a negative net margin of 762.92% and a negative return on equity of 13.49%. The firm had revenue of $1.25 million during the quarter, compared to analysts’ expectations of $0.98 million. On average, analysts expect that Janux Therapeutics will post -1.34 EPS for the current fiscal year.

Insider Transactions at Janux Therapeutics

In other news, major shareholder Ventures Xi L.P. Avalon sold 677,279 shares of Janux Therapeutics stock in a transaction dated Monday, June 3rd. The stock was sold at an average price of $54.75, for a total value of $37,081,025.25. Following the completion of the transaction, the insider now owns 3,271,216 shares of the company’s stock, valued at approximately $179,099,076. The transaction was disclosed in a legal filing with the SEC, which is available through the SEC website. In other Janux Therapeutics news, CFO Tighe Reardon sold 822,721 shares of the stock in a transaction on Monday, June 3rd. The stock was sold at an average price of $54.75, for a total transaction of $45,043,974.75. Following the sale, the chief financial officer now directly owns 633,673 shares in the company, valued at approximately $34,693,596.75. The sale was disclosed in a document filed with the SEC, which is accessible through the SEC website. Also, major shareholder Ventures Xi L.P. Avalon sold 677,279 shares of Janux Therapeutics stock in a transaction on Monday, June 3rd. The stock was sold at an average price of $54.75, for a total value of $37,081,025.25. Following the completion of the sale, the insider now directly owns 3,271,216 shares of the company’s stock, valued at approximately $179,099,076. The disclosure for this sale can be found here. Over the last three months, insiders have sold 3,000,000 shares of company stock valued at $164,250,000. Insiders own 35.40% of the company’s stock.

Institutional Investors Weigh In On Janux Therapeutics

Institutional investors have recently modified their holdings of the business. Nisa Investment Advisors LLC raised its stake in Janux Therapeutics by 10,740.0% during the 4th quarter. Nisa Investment Advisors LLC now owns 2,710 shares of the company’s stock valued at $29,000 after buying an additional 2,685 shares during the last quarter. Exchange Traded Concepts LLC grew its holdings in shares of Janux Therapeutics by 34.0% in the fourth quarter. Exchange Traded Concepts LLC now owns 14,204 shares of the company’s stock worth $152,000 after acquiring an additional 3,602 shares during the period. China Universal Asset Management Co. Ltd. increased its position in Janux Therapeutics by 82.4% during the first quarter. China Universal Asset Management Co. Ltd. now owns 9,743 shares of the company’s stock valued at $367,000 after acquiring an additional 4,400 shares during the last quarter. ProShare Advisors LLC bought a new position in Janux Therapeutics in the first quarter valued at about $251,000. Finally, Lester Murray Antman dba SimplyRich bought a new position in Janux Therapeutics in the first quarter valued at about $300,000. 75.39% of the stock is owned by hedge funds and other institutional investors.

About Janux Therapeutics

Janux Therapeutics, Inc, a clinical stage biopharmaceutical company, develops immunotherapies based on Tumor Activated T Cell Engagers (TRACTr) and Tumor Activated Immunomodulators (TRACIr) platforms technology to treat patients suffering from cancer. The company's clinical candidates comprise JANX007, a prostate-specific membrane antigen or PSMA-TRACTr, which is in Phase 1 clinical trial in adults for the treatment of metastatic castration-resistant prostate cancer (mCRPC) and the vasculature of other tumors; and JANX008, an epidermal growth factor receptor or EGFR-TRACTr that is in Phase 1 clinical trial for the treatment of multiple solid cancers, including colorectal cancer, squamous cell carcinoma of the head and neck, non-small cell lung cancer, and renal cell carcinoma.